2020StatPearlsRequires access

Von Willebrand Factor

Neeti Luke, Shivaraj Nagalli

Open publisher page 0 citations

Abstract

Von Willebrand disease (vWD) is a common bleeding disorder caused by quantitative or qualitative defects of the von Willebrand factor (vWF). The clinical management of vWD has evolved over the past few decades, but it continues to pose a diagnostic and therapeutic challenge. In current practice, desmopressin is the treatment of choice for type 1 vWD because it corrects the FVIII/vWF levels. However, in patients with type 3 vWD and some forms of type 1 and 2 vWD, desmopressin is not effective, and for these patients, replacement therapy containing FVIII and vWF concentrates are the mainstay of treatment.

About this research paper

What this paper is about

Von Willebrand disease (vWD) is a common bleeding disorder caused by quantitative or qualitative defects of the von Willebrand factor (vWF). The clinical management of vWD has evolved over the past few decades, but it continues to pose a diagnostic and therapeutic challenge. In current practice, desmopressin is the treatment of choice for type 1 vWD because it corrects the FVIII/vWF levels. However, in patients with type 3 vWD and some forms of type 1 and 2 vWD, desmopressin is not effective, and for these patients, replacement therapy containing FVIII and vWF concentrates are the mainstay of treatment.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Von Willebrand disease (vWD) is a common bleeding disorder caused by quantitative or qualitative defects of the von Willebrand factor (vWF). The clinical management of vWD has evolved over the past few decades, but it continues to pose a diagnostic and therapeutic challenge. In current practice, desmopressin is the treatment of choice for type 1 vWD because it corrects the FVIII/vWF levels. However, in patients with type 3 vWD and some forms of type 1 and 2 vWD, desmopressin is not effective, and for these patients, replacement therapy containing FVIII and vWF concentrates are the mainstay of treatment.

Key concepts: Desmopressin, Von Willebrand factor, Von Willebrand disease, Medicine, Pediatrics, Immunology, Internal medicine, Platelet

Back to paper searchBrowse research topicsOriginal source
Von Willebrand Factor — Research Paper | ScholarLens